alcaftadine ophthalmic (Rx)

Brand and Other Names:Lastacaft
  • Print

Dosing & Uses

AdultPediatric

Dosing Form & Strengths

ophthalmic solution

  • 0.25%

Allergic Conjunctivitis

Indicated for prevention of itching associated with allergic conjunctivitis

Instill 1 gtt to each eye daily

Dosing Form & Strengths

ophthalmic solution

  • 0.25%

Allergic Conjunctivitis

Indicated for prevention of itching associated with allergic conjunctivitis

<2 years: Safety and efficacy not established

≥2 years: As adults, instill 1 gtt to each eye daily

Next:

Adverse Effects

1-10%

Ocular

  • Irritation
  • Burning
  • Stinging
  • Redness
  • Pruritus
  • Eye discharge
  • Eye swelling
  • Erythema of eyelid
  • Eyelid edema

Nonocular

  • Nasopharyngitis
  • Headache
  • Influenza
  • Somnolence

Postmarketing reports

Lacrimation increased

Vision blurred

Hypersensitivity reactions including swelling of the face or allergic dermatitis

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

To minimize eye injury and contamination of dropper tip and solution, care should be taken not to touch eyelids or surrounding areas with dropper tip of bottle; keep bottle tightly closed when not in use

Keep bottle tightly closed when not in use

Do not use for contact lens–related irritation

Remove contact lenses before instillation

Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no adequate and well-controlled studies in pregnant women to inform a drug associated risk; there are limited data with use of drug in pregnant women; advise pregnant women of potential risk to fetus and mother; treatment should only be administered during pregnancy if potential benefit justifies potential risk to fetus and mother

Animal data

  • In embryofetal studies in rats and rabbits, oral administration of alcaftadine during period of organogenesis did not produce maternal or embryofetal toxicity at clinically relevant doses;

Lactation

There is no information regarding presence of drug in human milk, effects on breastfed infants, or on milk production to inform risk to an infant during lactation; the developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for treatment, and any potential adverse effects on breastfed infant from therapy

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

H1-receptor antagonist; inhibits histamine release from mast cells, decreases chemotaxis, and inhibits eosinophil activation

Pharmacokinetics

Absorption: Minimal

Half-Life: 2 hr

Peak Plasma Time: 0.25 hr; active metabolite 1 hr

Peak Plasma Concentration: 60 pg/mL (levels fell below limit of quantification by 3 hr); active metabolite 3 ng/mL

Protein Bound: 39.2%; active metabolite 62.7%

Metabolism: Non-CYP450 cytosolic enzymes to active metabolite carboxylic acid

Previous
Next:

Administration

Instructions

If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.